PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population

• Главные авторы: Wen-Yi Yang (Автор), Thibault Petit (Автор), Nicholas Cauwenberghs (Автор), Zhen-Yu Zhang (Автор), Chang-Sheng Sheng (Автор), Lutgarde Thijs (Автор), Erika Salvi (Автор), Benedetta Izzi (Автор), Christophe Vandenbriele (Автор), Fang-Fei Wei (Автор), Yu-Mei Gu (Автор), Lotte Jacobs (Автор), Lorena Citterio (Автор), Simona Delli Carpini (Автор), Cristina Barlassina (Автор), Daniele Cusi (Автор), Marc F. Hoylaerts (Автор), Peter Verhamme (Автор), Tatiana Kuznetsova (Автор), Jan A. Staessen (Автор)
• Формат: ‌
• Опубликовано: BMC, 2017-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Итог

Abstract Background Platelet Endothelial Aggregation Receptor 1 (PEAR1), a membrane protein highly expressed in platelets and endothelial cells, plays a role in platelet contact-induced activation, sustained platelet aggregation and endothelial function. Previous reports implicate PEAR1 rs12041331 as a variant influencing risk in patients with coronary heart disease. We investigated whether genetic variation in PEAR1 predicts cardiovascular outcome in a white population. Methods In 1938 participants enrolled in the Flemish Study on Environment, Genes and Health Outcomes (51.3% women; mean age 43.6 years), we genotyped 9 tagging SNPs in PEAR1, measured baseline cardiovascular risk factors, and recorded Cardiovascular disease incidence. For SNPs, we contrasted cardiovascular disease incidence of minor-allele heterozygotes and homozygotes (variant) vs. major-allele homozygotes (reference) and for haplotypes carriers vs. non-carriers. In adjusted analyses, we accounted for family clusters and baseline covariables, including sex, age, body mass index, mean arterial pressure, the total-to-HDL cholesterol ratio, smoking and drinking, antihypertensive drug treatment, and history of cardiovascular disease and diabetes mellitus. Results Over a median follow-up of 15.3 years, 238 died and 181 experienced a major cardiovascular endpoint. The multivariable-adjusted hazard ratios of eight PEAR1 SNPs, including rs12566888, ranged from 0.87 to 1.07 (P ≥0.35) and from 0.78 to 1.30 (P ≥0.15), respectively. The hazard ratios of three haplotypes with frequency ≥10% ranged from 0.93 to 1.11 (P ≥0.49) for mortality and from 0.84 to 1.03 (P ≥0.29) for a cardiovascular complications. These results were not influenced by intake of antiplatelet drugs, nonsteroidal anti-inflammatory drugs, or both (P-values for interaction ≥ 0.056). Conclusions In a White population, we could not replicate previous reports from experimental studies or obtained in patients suggesting that PEAR1 might be a susceptibility gene for cardiovascular complications.

Примечание

10.1186/s12881-017-0411-x
1471-2350